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Objective: Despite the widespread use of botulinum 
toxin in ambulatory children with spastic cerebral 
palsy, its value prior to intensive physiotherapy with 
adjunctive casting/orthoses remains unclear. 
Design: A pragmatically designed, multi-centre trial, 
comparing the effectiveness of botulinum toxin + in-
tensive physiotherapy with intensive physiotherapy 
alone, including economic evaluation. 
Subjects/patients: Children with spastic cerebral 
palsy, age range 4–12 years, cerebral palsy-severity 
Gross Motor Function Classification System levels I–
III, received either botulinum toxin type A + inten-
sive physiotherapy or intensive physiotherapy alone 
and, if necessary, ankle-foot orthoses and/or casting. 
Methods: Primary outcomes were gross motor func-
tion, physical activity levels, and health-related 
quality-of-life, assessed at baseline, 12 (primary 
end-point) and 24 weeks (follow-up). Economic out-
comes included healthcare and patient costs. Inten-
tion-to-treat analyses were performed with linear 
mixed models.
Results: There were 65 participants (37 males), with 
a mean age of 7.3 years (standard deviation 2.3 
years), equally distributed across Gross Motor Fun-
ction Classification System levels. Forty-one child-
ren received botulinum toxin type A plus intensive 
physio therapy and 24 received intensive physiother-
apy treatment only. At primary end-point, one statis-
tically significant difference was found in favour of 
intensive physiotherapy alone: objectively measu-
red percentage of sedentary behaviour (–3.42, 95% 
confidence interval 0.20–6.64, p = 0.038). Treatment 
costs were significantly higher for botulinum toxin 
type A plus intensive physiotherapy (8,963 vs 6,182 
euro, p = 0.001). No statistically significant differen-
ces were found between groups at follow-up. 
Conclusion: The addition of botulinum toxin type A 
to intensive physiotherapy did not improve the ef-
fectiveness of rehabilitation for ambulatory children 
with spastic cerebral palsy and was also not cost-
effective. Thus botulinum toxin is not recommended 
for use in improving gross motor function, activity 
levels or health-related quality-of-life in this cere-
bral palsy age- and severity-subgroup.
Key words: spastic cerebral palsy; botulinum toxin; physio­
therapy; cost­effectiveness. 
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Multi-level treatment with botulinum toxin type A (BoNT-A) is widely used in spastic cerebral 
palsy (CP). By reducing muscle spasticity/abnormal 
muscle tone, BoNT-A aims to improve an individual’s 
activity and participation, domains related to higher 
level of functioning, as described in the World Health 
Organization’s International Classification of Functio-
ning (ICF) (1). BoNT-A is prescribed for the majority 
of ambulatory children with spastic CP in most Wes-
tern countries (2) and treatment is repeated frequently 
throughout childhood (3). BoNT-A injections are not a 
stand-alone intervention and should be combined with 
additional, preferably activity-focused, interventions 
(4, 5). Leg muscle injections are usually combined 
with physiotherapy (PT) and, if necessary, additional 
casting and/or ankle-foot orthoses. The rationale for 
this is that BoNT-A may provide better conditions to 
optimize and reinforce the effects of PT and adjunctive 
interventions in combined treatment. 
In general, positive effects of combined treatment 
have been reported on outcomes at the ICF level of 
body function and structure (i.e. reducing muscle 
spasticity and hypertonia and improving range of 
motion). However, treatment effects on higher ICF 
levels of functioning remain unclear (4–6). Further-
more, there is a lack of clarity regarding the degree 
that positive outcomes of combined treatment can be 
attributed to BoNT-A (7–9), as a period of intensive, 
goal-directed PT without BoNT-A also seems to be 
effective (6, 10). BoNT-A treatment is burdensome 
(i.e. a toxin is injected, usually under anaesthesia) and 
costly. In addition, a potential industry-related conflict 
of interest regarding the effectiveness of BoNT-A has 
been reported recently (11). Hence, it is important to 
explicitly study the added value of BoNT-A in com-
bined intensive treatment. The aim of this study was 
therefore to determine the effectiveness and costs of 
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23Value of botulinum toxin for spastic CP
multi-level BoNT-A injections in combination with 
a 12-week period of intensive functional PT (BoNT-
A+iPT) compared with the effectiveness and costs 
of a 12-week period of intensive functional PT alone 
(only-iPT). Primary outcomes for effectiveness were 
gross motor function, physical activity levels and 
health-related quality of life.
METHODS
Study design and participants
A pragmatically designed, single-blind, multi-centre trial was 
performed to compare the effectiveness of BoNT-A+iPT with 
only-iPT. Randomized participants and those who had objec-
tions to randomization because, for various reasons, they stron-
gly preferred one of the interventions were both enrolled in the 
study. Thus, due to allowing inclusion of participants according 
to family preferences, this was not a fully randomized trial (12, 
13) and the study was conducted pragmatically. Power calcula-
tions (performed for the originally intended fully randomized 
trial) were based on simulation of 500 data-sets with mixed 
effect model analyses (α = 0.05, β = 0.20) using existing Gross 
Motor Function Measure (GMFM) data (14). A total sample size 
of 60 children was considered sufficient. Economic evaluation 
was performed from a societal perspective. 
Children were recruited from 2 Dutch university hospitals 
and 5 rehabilitation centres. During regular consultations with 
the spasticity-management team, experienced multidisciplinary 
teams of clinical professionals assessed children for eligibility. 
Inclusion criteria were: diagnosis of spastic CP (15), primarily 
lower extremity involvement (unilateral or bilateral), classified 
at levels I–III of the Gross Motor Function Classification System 
(GMFCS) (16), age range 4–12 years, and an indication for 
BoNT-A (4, 5). Exclusion criteria were: BoNT-A treatment < 6 
months or CP-related surgery < 12 months prior to enrolment, 
cognitively unable to understand instructions, presence of severe 
contractures or co-morbidity. The ethics committee of Erasmus 
MC approved the study, and the trial was registered in the Dutch 
Trial Register (NTR TC 1655). Written informed consent was 
obtained from parents/primary caregivers. 
Enrolment, randomization and blinding
Parents of eligible children were initially invited to participate 
on a randomized basis. If they declined, they were then offered 
participation in the group they preferred. The subjects who were 
randomized were centrally assigned to either BoNT-A+iPT or 
only-iPT by a computer-generated, independently provided, 
block randomization scheme with stratification by GMFCS 
level per measuring location (i.e. the university hospitals). The 
aim was to blind the outcome assessors, physiotherapists and 
those administering additional post-BoNT-A co-interventions. 
For randomized participants, allocation to intervention groups 
was concealed until after baseline measurements. Physio-
therapists and outcome assessors were asked to speculate the 
child’s suspected intervention group after primary end-point 
measurements. Blinding of physiotherapists and assessors in the 
group that received preferred treatment was also pursued and its 
success similarly assessed. All data were anonymized and coded 
prior to data analysis, which was performed by individuals not 
involved with the interventions or outcome assessments. 
Procedures
After baseline measurements, individual BoNT-A treatment 
plans were compiled based on clinical examination and instru-
mented gait analysis. Indications for co-interventions during the 
iPT period (i.e. serial casting and prescription or (re)alignment of 
ankle-foot orthoses (AFOs)) were also determined. In the BoNT-
A+iPT intervention group, BoNT-A was administered under 
general anaesthesia by experienced clinicians during individually 
scheduled 1-day hospitalizations. Treatment adhered to recom-
mendations pertaining to preparations, cautions, dose modifiers, 
localization techniques and safety aspects (European Consensus 
2009) (4). In all cases, preparations of botulinum toxin serotype 
A (Botox®, Allergan Inc., Eindhoven, The Netherlands) were 
used, and in each treated muscle group, the maximum allowed 
dose, in relation to children’s age and weight, was injected. 
The period of intensive functional PT (iPT) started one week 
after BoNT-A for the BoNT-A+iPT intervention group, and was 
individually scheduled for children in the only-iPT interven-
tion group. A guideline was developed based on best-available 
evidence (2010) (17, 18). During a 12-week period, children 
ideally had 3 45–60-min therapy sessions each week, with at 
least 1 rest day between sessions. Information about therapy 
content and patient compliance was determined using custom-
made therapy journals, which were completed by therapists after 
each session. Sessions were held at children’s schools and/or in 
private practices. The main therapy components were progres-
sive resistance exercises (PRE) based on current guidelines for 
typically developing children (17) and children with CP (i.e. 
intensity of 8–15 repetion maximum) (18) to improve strength 
and endurance, and functional goal-directed exercises with 
goals at the ICF activity level set by therapist and parents in 
dialogue. Due to large clinical heterogeneity, therapy content 
was individually tailored within the framework of the guideline, 
relying strongly on physiotherapists’ clinical reasoning abilities. 
All paediatric physiotherapists involved were experienced in 
treating children with CP. After the primary end-point measu-
rements, PT reverted to individuals’ pre-study intensity. 
In both intervention groups, 2–4 weeks of serial casting (i.e. 
below-knee walking casts changed weekly) could be prescribed 
in case of passive ankle dorsiflexion with extended knee less 
than 0°, starting approximately 1 week after iPT commenced 
(i.e. 2 weeks after BoNT-A), and ending when 0° dorsiflexion 
was possible. Therapy continued when children wore casts. If 
prescribed, (re)alignment of current or new AFOs was arranged 
as soon as possible.
Primary-end-point measurements were performed when 
individual 12-week iPT periods ended. Long-term follow-up 
measurements were completed 12 weeks thereafter (24 weeks). 
Independent assessors scored the clinical outcome measures and 
participants completed web-based questionnaires. Regarding 
assessment of safety and reporting of adverse events, all persons 
involved adhered to Good Clinical Practice (GCP) procedures.
Outcome measures
Three outcome measures assessing gross motor function, 
physical activity levels and generic health-related quality of 
life (HRQoL) were used as primary effectiveness outcomes. 
Children with CP can experience a good quality of life despite 
having significant functional limitations (19).
Gross motor function was measured with the item set version 
of the Gross Motor Function Measure (GMFM-66), a widely 
used observational instrument that scores the capacity of child-
J Rehabil Med 50, 2018
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Statistical analyses
First, the characteristics of participants and the different treat-
ment components in the 2 intervention groups were compared 
using conservative non-parametric tests. Subsequently, compa-
rative analysis of effectiveness of BoNT-A+iPT vs effectiveness 
of only-iPT at primary-end-point and follow-up were performed 
using linear mixed model analyses. In these intention-to-treat 
(ITT) analyses to estimate differences in treatment effectiveness 
we adjusted for the dependency of repeated observations in each 
subject (random intercept). We also adjusted for randomized/
preferred treatment participation, number of previous BoNT-A 
treatments, age and GMFCS level. The latter is the most relevant 
in all discussions related to management of spastic CP (5). All 
statistical analyses were carried out using IBM-SPSS statistics 
21; the level of statistical significance was set at p < 0.05. 
RESULTS
Between October 2009 and September 2013, 757 
children were assessed for eligibility, of whom 84% 
did not meet the inclusion criteria, mainly because they 
were classified as GMFCS levels IV–V or they did not 
fit the age range (Fig. 1). Of 123 families who were 
invited to participate, 43% declined, primarily due to 
ren with CP to perform gross motor skills (16). The item set 
version (GMFM-66-IS) is reliable, valid and responsive for 
determining changes in gross motor function in CP (20). 
Actual everyday physical activity levels were measured 
objectively using an ambulatory monitoring device (AM, 
Actigraph-GT3X+ 3D-accelerometer, 4.6 × 3.3 × 1.5 cm; 19 g, 
ActiGraph, Pensacola, FL, USA), validated for use in children 
with CP (21). Children wore the devices on an elastic belt 
positioned on the waist (on the less-affected side), and parents 
were instructed about donning and doffing the device. Devices 
were worn during the daytime for 7 days, except while sho-
wering/bathing or swimming. Accelerometer signals (sample 
frequency 30 Hz) were analysed using Actilife software (ver-
sion 6.6.2, ActiGraph). For all 3 axes, activity counts were 
calculated using a 5-s epoch length, and from this, a vector 
magnitude was calculated. Periods of continuous zero counts 
lasting 15 min or longer were defined as non-wear periods (and 
were excluded from further analyses). Days with at least 480 
min wear time were considered valid. The following outcome 
measures were calculated: total amount of activity counts per 
day (Total-counts), mean intensity of physical activity counts 
per min (CpM) and mean percentage of the day spent sedentary 
(%Sedentary, using Evenson cut-off points) (22). 
HRQoL was measured using child self- and proxy-reported 
questionnaires. Functional health status was measured using 
the Child Health Questionnaire – proxy version (CHQ-PF28). 
The CHQ is a generic, norm-referenced HRQoL 
instrument that measures physical and psychosocial 
well-being of children approximately ≥ 5 years of 
age (23). The DISABKIDS questionnaire condition-
specific CP module was used to measure the impact 
of this condition (24). The DISABKIDS-smiley self- 
and proxy-reported paediatric scales, in the form of 
”emoticon faces”, were used for scoring HRQoL (24). 
The commonly used preference-based Health Uti-
lities Index (HUI), which assesses a number of diffe-
rent quality of life domains, was the main instrument 
for economic evaluation (25). The HUI-15Q 15-item 
proxy questionnaire was used to classify children 
to 2 complementary HUI health state classification 
systems by applying HUI2 and HUI3 multi-attribute 
utility formulas (25). 
Economic evaluation was performed from a so-
cietal perspective (26) and included healthcare and 
patient costs. Data on healthcare use and patient time 
were obtained from standardized parent/caregiver 
diaries (for iPT compliance, data were double check-
ed with therapists’ administrations), hospital- and 
pharmacotherapeutic-registration and information 
systems. To calculate the total intramural medical 
costs per BoNT-A treatment, we distinguished re-
ferral, consultations of multidisciplinary spasticity-
teams, standardized gait analysis before and after 
treatment, pre-anaesthetic assessment, BoNT itself, 
injections under full anaesthesia, a 1-day hospital stay 
and post-treatment medical monitoring. For the most 
important cost items, unit prices were determined via 
micro-costing methods (27). This was based on a 
detailed inventory and measurement of all resources 
used (manpower, equipment, materials, housing and 
overhead). If no differences in effect between the 2 
interventions were found, the economic evaluation 
converted to a cost minimization analysis (CMA).
Fig. 1. Flow diagram of the SPACE BOP (SPAstic cerebral palsy; Cost­Effectiveness 
of BOtulinum toxin and Physiotherapy) study. BoNT­A: botulinum toxin type A; iPT: 
intensive physiotherapy PT: physiotherapy; ITT: intention­to­treat; AFO: ankle­
foot orthoses; HRQoL: health­related quality of life; AM: Ambulatory Monitoring 
device; GMFM: Gross Motor Function Measure.
n=757 assessed for eligibility (October 2009 – September 2013) 
n=692 excluded 
    n=634 did not meet inclusion criteria 
    n=53 declined to participate  
    n=5 other reasons 
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n=41 included in ITT analyses 
Primary end point: 
n=0 GMFM data missing 
n=2 AM data missing 
n=0 HRQoL data missing 
Follow-up: 
n=0 GMFM data missing 
n=3 AM data missing 
n=0 HRQoL data missing 
n=24 included in ITT analysis 
Primary end point: 
n=0 GMFM data missing 
n=2 AM data missing 
n=0 HRQoL data missing 
Follow-up: 
n=0 GMFM data missing 
n=2 AM data missing 
n=1 HRQoL data missing 
n=41 received BoNT-A+iPT intervention 
    n=12 randomised participation 
    n=29 prefered BoNT-A+iPT 
n=24 received  only-iPT intervention 
    n=14 randomised participation 
    n=10 prefered only-iPT 
n=0 lost to follow-up  
n=22 returned to individual pre-
allocation PT intensity  
n=1 received BoNT-A+iPT 
intervention  
n=1 received local BoNT-A injections 
to optimise fit of AFO 
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25Value of botulinum toxin for spastic CP
perceived additional burden. Finally, 65 children with 
spastic CP were enrolled, including 40% randomized 
participants. Within this latter group, 62% of families 
preferred 1 of the interventions (27% BoNT-A+iPT and 
35% only-iPT). Overall, only 10 families (15%) were 
neutral regarding which intervention they received. 
In total, there were 37 boys and 28 girls, mean age 
7 years 4 months (standard deviation (SD) 2 years, 4 
months). Fourteen participants had unilateral spastic 
CP subtype; 51 had bilateral spastic CP subtype; and 
19, 23 and 23 children were classified as GMFCS levels 
I, II and III, respectively. There were no drop-outs and 
few missing data (Fig. 1). 
Shortly after their baseline measurements, 41 child-
ren received BoNT-A+iPT and 24 children started 
only-iPT. In the 2 intervention groups, participants 
were evenly distributed over GMFCS levels, but in 
the only-iPT group there were more children with 
unilateral CP (explaining a smaller number of casting 
periods) and they were also younger (Table I). The 2 
intervention groups differed significantly regarding 
BoNT-A history (p = 0.002) and random participation 
(p = 0.021), both factors for which we planned to adjust 
in the comparative effectiveness analyses. Mean and 
SD number of injected BoNT-A units per kg body-
weight for children receiving BoNT-A+iPT were 9 (SD 
5), 17 (SD 5) and 17 (SD 4), for GMFCS levels I, II and 
III, respectively. Comparison of baseline scores of the 2 
intervention groups with conservative non-parametric 
tests showed that none of the outcome measures dif-
fered significantly. For various reasons, masking of 
their outcome assessor or physiotherapist accidentally 
Table I. Characteristics of participants and treatment components for the 2 intervention groups
BoNT­A+iPT
n = 41
Only­iPT
n = 24 p­value
Characteristics of participants
GMFCS level: I/II/III, % 29/32/39 29/42/29 0.656
CP type: unilateral/bilateral, % 17/83 29/71 0.258
Age, years and months, mean (SD) 7 y 6 m (2 y 5 m) 6 y 11 m (2 y 4 m) 0.324
7–/7+ years of age, % 51/49 58/42 0.578
Sex: boys/girls, % 54/46 62/38 0.486
Number of weeks of gestation, mean (SD) 33 (5) 34 (4) 0.554
Regular school/special school, % 49/51 46/54 0.818
Number of previous BoNT-A treatment 0/1/≥ 2, % 20/34/46 62/17/21 0.002*
Reported unpleasant experiences previous BoNT­A treatment, % 30 56 0.168
No use of assistive devices, % 2 4
Uses orthopaedic shoes and/or AFO, % 39 42 0.888
Uses multiple devices, including (wheeled) walker, wheelchair, % 59 54
Randomized participation, % 29 58 0.021*
Characteristics of treatment components
Prescribed number of BoNT­A units/kg bodyweight, mean (SD)a 15 (6) 13 (6) 0.110
Prescribed number of BoNT­A units per joint level, mean (SD) 
Hip joint levela 49 (21) 58 (35) 0.549
Knee joint levela 129 (44) 128 (65) 0.668
Ankle joint levela 89 (47) 89 (38) 0.886
Prescribed number of BoNT­A units per muscle, mean (SD)
m psoasa 12 (18) 9 (16) 0.372
mm adductorsa 9 (16) 11 (30) 0.266
m gracilisa 30 (20) 30 (29) 0.653
m semimembranosusa 31 (19) 33 (28) 0.866
m semitendinosusa 32 (19) 32 (26) 0.948
m rectus femorisa 11 (19) 1 (7) 0.003*
m gastrocnemius medialisa 32 (23) 24 (24) 0.092
m gastrocnemius lateralisa 21 (23) 19 (22) 0.722
m soleusa 6 (14) 2 (7) 0.357
m tibialis posteriora 5 (15) 5 (13) 0.606
other lower leg musclesa 3 (10) 1 (3) 0.159
Casting period, uni­ or bilateral casting, % 59 33 0.072
Problem(s) with cast(s) during iPT period, % 29 38 0.663
New AFO(s) or realignment current AFO(s), % 34 29 0.677
Problem(s) with AFO(s) during iPT period, % 43 43 1.000
Number of sessions during the 12­week iPT period, mean (SD)b 31 (6) 31 (4) 0.989
Number of iPT min during the 12­week iPT period, mean (SD)b 1,290 (389) 1,196 (250) 0.528
Number of PT min between 12 and 24 weeks, mean (SD)c 700 (393) 558 (236) 0.151
*p ≤ 0.05.
aChildren in the only­iPT intervention group did not receive BoNT­A injections, but treatment plans were made for all participants to determine individual costs, 
~ Prescribed numbers of BoNT­A units were based on 116 legs (n =75 in the BoNT­A+iPT group and n = 41 in the Only­iPT group), bBased on therapy journals of 
n = 64 children in which min spent with progressive resistance exercises (PRE) exercises and functional goal­directed exercises were noted, and cbased on PT’s 
business administration of n = 65 children.
AFO: ankle-foot orthoses; GMFCS: Gross Motor Function Classification System; BoNT-A: botulinum toxin type A; iPT: intensive physiotherapy; AFO: ankle foot 
orthosis; CP: cerebral palsy; SD: standard deviation; PT: physiotherapy.
J Rehabil Med 50, 2018
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failed before primary end-point was reached for 37% 
and 69% of the participants, respectively.
While adjusting for GMFCS level, BoNT-A history, 
age and randomized/preferred treatment allocation in 
the mixed models ITT analyses, at primary end-point 
(baseline to 12 weeks), we found only one statistically 
significant difference in treatment effect between inter-
vention groups: AM-measured % of sedentary physical 
activity behaviour was in favour of only-iPT (Table II). 
At follow-up (baseline to 24 weeks), we did not find 
any statistically significant differences in treatment 
effects between the 2 interventions (Table II). 
The presence of only 1 statistically significant 
difference in effect between the 2 interventions (in 
favour of only-iPT), plus the absence of statistically 
significant differences for the Health Utility Index 
(HUI)-uti-mark3 and HUI-uti-mark2 utility scores, 
prompted us to change our economic evaluation into 
a cost-minimization analysis. Notably, however, the 
HUI-uti-mark3 and HUI-uti-mark2 utility scores all 
showed clinically meaningful improvements of ≥ 0.03 
points (25) at the group level (n = 65) at both 12 and 
24 weeks. The total cost per child for treatment up 
to primary end-point was significantly higher for 
Table II. Linear mixed models analyses at the primary end­point (12 weeks) and follow­up (24 weeks)
BoNT­A +iPT 
base
Mean
Only­iPT 
base
Mean
BoNT­A +iPT
12 weeks
Mean
Only­iPT
12 weeks
Mean
Estimated 
difference in 
treatment effecta 95% CI p­value
Baseline – 12-week comparison
Gross Motor Function Measure (0–100)
GMFM66­IS score 69.0 70.2 69.6 72.1 1.25 –0.21–2.70 0.092
AM – actual everyday physical activity level 
Total­counts (*1,000) 553 559 541 621 73.7 –11.6–158.9 0.089
Counts per min 808 846 803 916 76.4 –47.6–200.5 0.222
% Sedentary 72.3 71.1 72.7 68.0 3.42 0.20–6.64 0.038*
Child Health Questionnaire (0–100)
CHQ­PF28­Physical 35.4 39.2 37.7 38.1 –3.48 –10.19–3.22 0.303
CHQ­PF28­Psychological 48.6 50.2 48.8 49.1 –1.25 –6.05–3.55 0.603
DISABKIDS Questionnaires (0–100)
CP­impact 63.0 66.4 66.7 67.6 –2.45 –9.65–4.75 0.499
Smileys­proxy 70.1 73.6 67.4 75.1 4.18 –1.90–10.25 0.174
Smileys­child 64.3 74.1 61.6 74.9 3.44 –4.58–11.46 0.394
Health Utility Index (0–1)
HUI­uti­mark3 0.50 0.50 0.59 0.58 –0.009 –0.120–0.101 0.870
HUI­uti­mark2 0.70 0.70 0.75 0.74 –0.005 –0.078–0.067 0.881
Baseline – 24-week comparison
Gross Motor Function Measure (0–100)
GMFM66­IS score 69.0 70.2 70.8 72.6 0.63 –1.37–2.63 0.530
AM – actual everyday physical activity level
Total­counts (*1,000) 549 556 586 539 –54.2 –133–24.3 0.172
Counts per min 803 841 868 815 –89.6 –196–17.1 0.098
% Sedentary 72.5 71.2 71.6 71.5 –1.17 –1.69–4.01 0.412
Child Health Questionnaire (0–100)
CHQ­PF28­Physical 35.3 39.2 37.2 39.0 –2.80 –8.45–2.85 0.325
CHQ­PF28­Psychological 48.5 50.3 50.6 52.0 –0.32 –4.44–3.80 0.877
DISABKIDS Questionnaires (0–100)
CP­impact 63.0 66.2 66.9 69.5 –0.62 –8.03–6.79 0.867
Smileys­proxy 70.1 73.5 67.0 76.2 5.73 –1.11–12.57 0.099
Smileys­child 64.2 74.3 66.1 73.6 –2.54 –10.54–5.46 0.527
Health Utility Index (0–1)
HUI­uti­mark3 0.50 0.50 0.55 0.57 0.017 –0.098–0.131 0.771
HUI­uti­mark2 0.70 0.70 0.74 0.73 0.001 –0.080–0.078 0.980
*p ≤ 0.05.
aFor the estimated difference in treatment effect a negative number is in favour of BoNT­A+iPT treatment, and a positive number is in favour of only­iPT treatment 
at the group level. For the GMFM66­IS, CHQ, DISABKIDS and HUI scores, higher scores indicate better outcomes or adjustment to CP. For the AM outcome 
measures, higher total­counts (*1,000) and CpM scores indicate better outcomes, for AM % Sedentary, lower scores indicate better outcomes.
CI: confidence interval. AFO: ankle-foot orthoses; BoNT-A: botulinum toxin type A; iPT: intensive physiotherapy; GMFM66-IS: Gross Motor Function Measure-66, 
item set version; AM: Ambulatory Monitoring device; CHQ­PF28: Child Health Questionnaire ­ proxy version; CP: cerebral palsy; HUI: Health Utility Index.
Table III. Cost comparison
Cost category
BoNT­A+iPT
n = 41
Only­iPT
n = 24
Pre­treatment trajectory (euro) 883 883
BoNT­A treatment procedure (euro) 2,170 0
iPT treatment period (euro) 4,448 4,096
Plaster cast(s) and/or AFO(s) trajectories* (euro) 1,082 823
Productivity loss and travel costs parents (euro) 380 380
Total costs per child (euro) 8,963 6,182
p = 0.001 (bootstrap)
*Differences in costs for casts and AFOs are largely related to a higher percentage 
of children with bilateral CP type in the BoNT­A+iPT treatment group.
BoNT­A: botulinum toxin type A; iPT: intensive physiotherapy; AFO: ankle foot 
orthosis; CP: cerebral palsy.
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27Value of botulinum toxin for spastic CP
BoNT-A+iPT than for only-iPT (8,963 vs 6,182 euro, 
p = 0.001, Table III). The mean difference in cost 
between the 2 interventions was 2,781 euro, of which 
78% was related to BoNT-A procedures, 13% to iPT 
periods and 9% to casting and/or AFOs. 
There were no serious side-effects and/or adverse 
events related to BoNT-A and/or iPT, but casting pe-
riods and/or (re)alignment of AFOs were complicated 
in a number of cases (Table I). Because the proportion 
of children with casting periods nearly differed sig-
nificantly between groups, we performed a post-hoc 
analysis adjusting for the presence/absence of casting 
periods in the mixed models; however, this did not 
change the present findings. 
DISCUSSION
There is an international consensus that BoNT-A 
should not be used as stand-alone treatment; adjunctive 
interventions to lower extremity BoNT-A injections, 
such as casting, orthotic management and especially a 
period of (intensive) PT, are essential components of 
post-BoNT-A care (4). However, historically, BoNT-
A is the actual adjunctive intervention (5). Therefore, 
we explicitly studied the added value of multi-level 
BoNT-A injections preceding a period of individually 
tailored iPT (which was equally intensive in both 
intervention groups) and the co-interventions casting 
and/or AFO (which were prescribed employing the 
same policy in both intervention groups) on clinical 
outcome at the higher ICF levels. With one exception 
in favour of only-iPT (AM-measured percentage of 
sedentary physical activity behaviour), we did not find 
statistically significant differences between the BoNT-
A+iPT and only-iPT interventions for primary effect 
outcomes, whereas the mean treatment costs per child 
were significantly higher for BoNT-A+iPT. 
Previous studies have discussed the uncertainty 
regarding the degree to which positive effects of com-
bined BoNT-A and iPT could be attributed to BoNT-A 
or to higher intensity of PT (7–9). Debate regarding 
the optimal BoNT-A dose is ongoing (4, 5, 28), and 
recommendations regarding the ideal dose remain 
expert-based. In our study, the medical specialists had 
ample experience with BoNT-A, and they applied the 
maximum recommended BoNT-A doses per large mus-
cle group. Adjunctive casting and/or (re)alignment of 
AFOs are part of usual care, but are not necessary for 
every child with spastic CP. The proportion of children 
who had problems with their cast(s) during the iPT 
period was somewhat higher in the only-iPT treatment 
group; however, casting in the BoNT-A+iPT group 
did not add to improved effectiveness of combined 
treatment at the group level. 
Critical appraisal of the literature regarding the ef-
fectiveness of BoNT-A shows that research questions 
have mainly been based on an implicit assumption that 
BoNT-A is the most active component in combined 
treatment periods. Positive clinical experiences with 
combined BoNT-A and other therapies may have been 
unjustly attributed to BoNT-A injections. This may 
also explain the difficulties in randomization that we 
and others (29) experienced, exacerbated by BoNT-A 
safety discussions preceding our study (6). 
As iPT appears to be the dominant component for 
effectiveness in our study, future research should also 
focus on how to optimize PT content and planning. 
Currently there is little evidence regarding how to 
organize PT to be optimally cost-effective (4, 5, 10). 
The large heterogeneity in spastic CP emphasizes that 
individualized assessment and treatment are indeed 
essential (28). However, lack of added value of BoNT-
A at the group level does not necessarily imply that 
children with CP cannot benefit from the injections. 
There may be a subgroup within the CP population and/
or particular treatment outcomes for which BoNT-A is 
of added value. This would probably be more easily 
identified by setting up CP patient registries. As stated 
by Damiano, it is important not only to focus on mean 
group results, but to design studies that provide insight 
into what works for which groups of patients (30). 
The main limitations of the current study were its 
pragmatic design, with 40% randomized participants, 
and the relatively small sample size of 65 children. A 
fully randomized controlled trial with a larger number 
of participants would have been more optimal, inclu-
ding for the economic evaluation. However, there are 
practical limitations to randomized controlled trials in 
rehabilitation research (12, 13, 31). It was difficult to 
convince parents to permit their children to participate 
randomly because of the strong preferences for one of 
the interventions (which we found surprising since we 
compared 2 ”fully fledged” interventions). Once in the 
study, however, families were highly motivated, which 
resulted in zero drop-outs and very few missing data, 
both adding to statistical power. It has to be noted, 
however, that our original power calculations may not 
have been completely valid for the present number of 
participants and the distribution across intervention 
groups. In addition, blinding of outcome assessors and 
physical therapists accidentally failed for a number of 
participants, which is a typical difficulty inherent to 
this type of research (4). Large heterogeneity (even 
within this subgroup) of the CP population also limits 
the feasibility of tightly controlling an intervention. 
As shown in Table I, there were some imbalances 
between the larger group that received BoNT-A+iPT 
and the smaller group that received only-iPT, which 
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may have introduced some bias. Having more severe 
spastic CP and being older increased the chances of a 
more extensive BoNT-A history, which may have been 
perceived as (un)pleasant, thereby explaining prefe-
rences, and objections to randomization. It appeared 
more difficult to identify and enrol participants who 
preferred only-iPT because BoNT-A+iPT is a generally 
accepted and most commonly prescribed treatment 
combination for ambulatory children with spastic CP. 
We note that it has been reported that receiving prefer-
red treatment does not affect outcomes (32). 
For multicollinearity and to maximize statistical po-
wer, we only adjusted for BoNT-A history, GMFCS le-
vel, age and (non-)randomized participation in the com-
parative analyses. Of course, we realize that the latter 
adjustment is debatable from a statistical point of view. 
Unfortunately there were no children with GMFCS 
level III in the randomized BoNT-A+iPT subgroup. 
This was due to a blockwise randomization scheme 
stratified by GMFCS level per measuring location, 
with a block length of 4 in the first block and a length 
of 2 in subsequent blocks. Consequently, baseline dif-
ferences between the 2 intervention groups were larger 
for randomized participants than for non-randomized 
participants. For this reason, and because there were 
no differences between the 2 intervention groups re-
garding their baseline scores and the most important 
patient and treatment characteristics, it was considered 
justified to perform analyses of BoNT-A+iPT vs only-
iPT with all participants in one comparison. However, 
because these issues may limit interpretability of our 
findings, we strongly advocate additional research into 
the added value of BoNT-A to confirm our findings. 
The fact that all intervention-related procedures largely 
resembled routine practice in the Netherlands and that 
a subgroup was given their preferred treatment adds 
to the generalizability of results. However, it remains 
unclear to what degree improvements in our study over 
time were related to natural development, as we did 
not have a control group without intervention. 
To our knowledge, this industry-independent study is 
the first to specifically study the added value of BoNT-
A injections in a widely used treatment combination, 
with equally highly intensive periods of physiotherapy, 
and, if necessary, adjunctive casting and/or AFOs in 
both intervention groups. In conclusion, at the group 
level, BoNT-A injections do not improve clinical effect 
outcomes compared with iPT alone and are not cost-
effective. Thus, both from a clinical and an economic 
viewpoint, it is time to critically reconsider the use of 
BoNT-A injections in treatment aiming at improving 
gross motor function, physical activity levels and/or 
HRQoL of 4–12 year-old children with spastic CP. 
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